The Role of Oclacitinib in the Management of Ischemic Dermatopathy in Four Dogs
April 2019
in “
Veterinary dermatology
”
New to Prednisolone? There is a guide in the encyclopedia. Read the guide → Studysummary This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study described the use of oclacitinib, a nonselective Janus-kinase inhibitor, in managing ischaemic dermatopathy in four mixed-breed dogs that were refractory to conventional immunosuppression. The dogs, aged 6 to 9 months, presented with generalized patchy alopecia, scarring, and ulcerative dermatitis. Initial treatments with glucocorticoids and adjuvant immunosuppressants failed to achieve complete remission. However, the administration of oclacitinib at 0.4-0.7 mg/kg twice daily, alongside a tapering regimen of oral prednisolone, led to full clinical remission within four weeks, with prednisolone being discontinued within eight weeks. Remission was maintained in two dogs with reduced oclacitinib doses, while the other two required continued twice-daily administration. The findings suggested that oclacitinib could be a valuable immunosuppressive adjuvant for treating severe or refractory ischaemic dermatopathy, warranting further investigation into its safety, efficacy, and mechanism of action.
